B+
Bull case
25%
Probability
Target price
$0.42
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
MDCX
MedicusANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Pfizer collaboration materially improves external validation and could provide development funding, strategic support, and contingent economic upside around CD228V. SkinJect and Teverelix also have multiple regulatory and clinical milestones ahead.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Additional equity or debt financing may dilute shareholders or increase financial obligations.
Momentum
11
Value
41
Sentiment
92
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.18 · Bull $0.42 · Bear $0.08Analysis 2026-09-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $4.48
Why
Momentum11 · Δ7d -
Value41 · Δ7d 0.0
Sentiment92 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Additional equity or debt financing may dilute shareholders or increase financial obligations.
- • CD228V is early clinical-stage and the Pfizer agreement does not establish clinical efficacy or commercial success.
- • This remains a $16 million-capitalization, early-stage biotech with substantial execution, regulatory, clinical, financing, and dilution risk.
Catalyst clock
2026-12-03
Pfizer CD228V co-development and license agreement
Lead driver: Sentiment · See AI snapshot
Momentum
11
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-5.2
Sentiment
92
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 10.9 / Value 41.2 / Sentiment 92.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-04. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.18
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.08
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$16.43M
Beta
-
Shares Out
22.03M
P/E (TTM) · Derived
-0.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.98
Rev YoY
-
EPS YoY
-51.2%
Gross Margin
-
Op Margin
-
Net Debt
-$2.36M
Current Ratio
1.57
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data